MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 206 filers reported holding MYRIAD GENETICS INC in Q1 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $755,404 | -33.4% | 47,095 | -3.7% | 0.00% | -40.0% |
| Q2 2023 | $1,133,827 | +1.9% | 48,914 | +2.1% | 0.01% | 0.0% |
| Q1 2023 | $1,112,856 | +136112.5% | 47,906 | -14.9% | 0.01% | +25.0% |
| Q4 2022 | $817 | -25.3% | 56,325 | -1.6% | 0.00% | -20.0% |
| Q3 2022 | $1,093 | -99.9% | 57,262 | +5.9% | 0.01% | 0.0% |
| Q2 2022 | $982,000 | -24.6% | 54,062 | +4.7% | 0.01% | 0.0% |
| Q1 2022 | $1,302,000 | +7.8% | 51,659 | +18.0% | 0.01% | +25.0% |
| Q4 2021 | $1,208,000 | -13.8% | 43,771 | +1.0% | 0.00% | -20.0% |
| Q3 2021 | $1,401,000 | +3.3% | 43,354 | -2.2% | 0.01% | 0.0% |
| Q2 2021 | $1,356,000 | -0.4% | 44,335 | -0.9% | 0.01% | -16.7% |
| Q1 2021 | $1,362,000 | +52.3% | 44,735 | -1.0% | 0.01% | +50.0% |
| Q4 2020 | $894,000 | +55.7% | 45,197 | +2.7% | 0.00% | +33.3% |
| Q3 2020 | $574,000 | +15.0% | 43,991 | 0.0% | 0.00% | +50.0% |
| Q2 2020 | $499,000 | -26.2% | 43,991 | -6.9% | 0.00% | -50.0% |
| Q1 2020 | $676,000 | -47.9% | 47,258 | -0.9% | 0.00% | -33.3% |
| Q4 2019 | $1,298,000 | -17.0% | 47,690 | -12.7% | 0.01% | -14.3% |
| Q3 2019 | $1,564,000 | +10.8% | 54,628 | +7.4% | 0.01% | 0.0% |
| Q2 2019 | $1,412,000 | -14.5% | 50,845 | +2.3% | 0.01% | -12.5% |
| Q1 2019 | $1,651,000 | +13.2% | 49,705 | -1.0% | 0.01% | 0.0% |
| Q4 2018 | $1,459,000 | -30.7% | 50,186 | +9.7% | 0.01% | -20.0% |
| Q3 2018 | $2,105,000 | +18.5% | 45,763 | -3.7% | 0.01% | +11.1% |
| Q2 2018 | $1,776,000 | +22.2% | 47,523 | -3.4% | 0.01% | +28.6% |
| Q1 2018 | $1,453,000 | -22.2% | 49,184 | -9.5% | 0.01% | -12.5% |
| Q4 2017 | $1,867,000 | -14.4% | 54,349 | -9.8% | 0.01% | -27.3% |
| Q3 2017 | $2,180,000 | +31.6% | 60,266 | -5.9% | 0.01% | +37.5% |
| Q2 2017 | $1,656,000 | +32.5% | 64,075 | -1.6% | 0.01% | +33.3% |
| Q1 2017 | $1,250,000 | -79.3% | 65,125 | -58.3% | 0.01% | -82.4% |
| Q3 2014 | $6,028,000 | -0.9% | 156,300 | 0.0% | 0.03% | 0.0% |
| Q2 2014 | $6,083,000 | +99.9% | 156,300 | +75.6% | 0.03% | +88.9% |
| Q1 2014 | $3,043,000 | – | 89,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |